FDA reiterates risks of antimalarial drug use for COVID-19, as study into efficacy ends early due to deaths – TechCrunch

[ad_1] The U.S. Food and Drug Administration (FDA) has issued a new warning about the known side effects of hydroxychloroquine and chloroquine, two antimalarial drugs (also used in the treatment of chronic rheumatoid arthritis and lupus), on the same day that a group of researchers published a paper in the Journal of the American Medical…